Key Takeaways
- Cinven's CEO and CFO/COO are reportedly stepping down from their positions following reports that the UK's Competition and Markets Authority (CMA) is seeking personal disqualification orders against them over alleged drug price gouging.
- The CMA's pursuit of Competition Disqualification Orders (CDOs) could ban the executives from managing any UK company for up to 15 years, setting a significant precedent for holding private equity fund directors personally liable for anti-competitive conduct by portfolio companies.
- This development comes after a May 2025 Court of Appeal ruling that reinstated a £51.9 million fine against private equity firm Cinven for "excessive and unfair pricing" of liothyronine tablets by its former portfolio company, Advanz Pharma, which saw prices increase by over 1,110%.
- Cinven has faced multiple fines from the CMA, totaling over £88 million in recent years, for anti-competitive practices related to various essential medicines, including prochlorperazine and hydrocortisone tablets.
International private equity firm Cinven is reportedly undergoing a significant leadership change, with its CEO and CFO/COO stepping down amidst the risk of a ban by the UK's Competition and Markets Authority (CMA) over allegations of drug price gouging. This move follows intense scrutiny and a series of substantial fines levied against the firm and its former portfolio companies for anti-competitive practices in the pharmaceutical sector.
The CMA is reportedly seeking Competition Disqualification Orders (CDOs) against Cinven's CEO, Supraj Rajagopalan, and CFO/COO, Alex Leslie, marking a potentially unprecedented step in UK competition enforcement. If approved by the courts, these orders could prohibit the executives from serving as directors of any UK company for up to 15 years, holding private equity fund directors personally accountable for the anti-competitive behavior of their portfolio firms.
This latest development is closely linked to a May 2025 ruling by the Court of Appeal, which upheld the CMA's 2021 decision against Advanz Pharma and Cinven. The court reinstated a £51.9 million fine against Cinven for "excessive and unfair pricing" of liothyronine tablets, a crucial thyroid hormone medication. The CMA found that Advanz Pharma, under Cinven's ownership, inflated the price of liothyronine tablets by over 1,110% between 2009 and 2017, significantly impacting NHS spending.
Cinven's history with UK regulators has been fraught with challenges. In February 2022, the firm was hit with another fine, sharing a £15.5 million penalty related to its past ownership of drug distributor Focus, which engaged in a profit-sharing agreement to eliminate competition for the anti-nausea drug prochlorperazine. This led to a staggering 700% price increase for the medication over four years. Prior to this, Cinven also faced a £20.9 million fine in 2021 for overcharging the NHS for hydrocortisone tablets.
The ongoing regulatory pressure underscores a broader trend of increased scrutiny on private equity firms operating in essential sectors like healthcare, particularly concerning pricing practices that can directly affect public services and consumer costs. The potential for personal disqualification of top executives signals a more aggressive stance by regulators to deter anti-competitive conduct and ensure fair market practices.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.